The Ultimate Austedo Dosing Guide: Everything You Need to Know

When it comes to managing symptoms of Huntington's disease and tardive dyskinesia, Austedo (deutetrabenazine) has become a popular treatment option. However, understanding the proper dosing guidelines is crucial to ensure its effectiveness and minimize potential side effects. In this comprehensive dosing guide, we will cover everything you need to know about Austedo dosing, including dosing recommendations, adjustment protocols, and important considerations.

Dosing Recommendations:

The recommended starting dose of Austedo for patients with Huntington's disease is 6 mg once daily. The dose may be titrated up by 6 mg increments at weekly intervals based on the patient's response and tolerability. The maximum recommended dose is 48 mg per day.

For patients with tardive dyskinesia, the recommended starting dose of Austedo is 6 mg once daily. The dose may be titrated up by 6 mg increments at weekly intervals based on the patient's response and tolerability. The maximum recommended dose is 48 mg per day.

Adjustment Protocols:

It is important to monitor patients closely for adverse effects and therapeutic response when titrating Austedo doses. If intolerable side effects occur, dose reduction or discontinuation may be necessary. Additionally, certain medications may interact with Austedo, requiring dose adjustments or monitoring.

Important Considerations:

Before starting Austedo, healthcare providers should assess patients for potential risk factors, including hepatic impairment and QTc prolongation. Regular monitoring of hepatic function, electrocardiograms, and psychiatric symptoms is recommended during treatment with Austedo.

Overall, proper dosing of Austedo is essential for achieving optimal therapeutic outcomes while minimizing the risk of adverse effects. By following the dosing recommendations, adjustment protocols, and important considerations outlined in this guide, healthcare providers can help patients effectively manage their symptoms of Huntington's disease and tardive dyskinesia with Austedo.